36 / 70
CARDIOVASCULAR JOURNAL OF AFRICA • Volume 30, No 5, September/October 2019
278
AFRICA
8.
Horst M, Mehlhorn U, Hoerstrup SP, Suedkamp M, de Vivie ER.
Cardiac surgery in patients with end-stage renal disease: 10-year experi-
ence.
Ann Thorac Surg
2000;
69
: 96–101.
9.
Herzog CA, Gilbertson DT. Comparative long-term survival of general
Medicare patients with surgical versus percutaneous coronary interven-
tion in the era of drug-eluting stents and impact of chronic kidney
disease.
Circulation
2008;
118
: 741.
10. Toole JM, Stroud MR, Kratz JM, Crumbley AJ, Crawford FA Jr,
Ikonomidis JS. Valve surgery in renal dialysis patients.
J Heart Valve Dis
2006;
15
: 453–458.
11. Simsir SA, Kohlman-Trigoboff D, Flood R, Lindsay J, Smith BM. A
comparison of coronary artery bypass grafting and percutaneous trans-
luminal coronary angioplasty in patients on hemodialysis.
Cardiovasc
Surg
1998;
6
: 500–505.
12. Herzog CA, Ma JZ, Collins AJ. Long-term outcome of dialysis patients
in the United States with coronary revascularization procedures.
Kidney
Int
1999; b: 324–332.
13. Bruschi G, Colombo T, Botta L,
et al.
Off-pump coronary revasculariza-
tion in chronic dialysis-dependent patients: Early outcomes at a single
institution.
J Cardiovasc Med
(Hagerstown) 2010;
11
: 481–487.
14. Franga DL, Kratz JM, Crumbley AJ, Zellner JL, Stroud MR, Crawford
FA. Early and long-term results of coronary artery bypass grafting in
dialysis patients.
Ann Thorac Surg
2000;
70
: 813–819.
15. Horai T, Fukui T, Tabata M, Takanashi S. Early and mid-term results
of off-pump coronary artery bypass grafting in patients with end-stage
renal disease: Surgical outcomes after achievement of complete revascu-
larization.
Interact Cardiovasc Thorac Surg
2008;
7
: 218–221.
16. Diegeler A, Hirsch R, Schneider F,
et al.
Neuromonitoring and neuro-
cognitive outcome in off-pump versus conventional coronary bypass
operation.
Ann Thorac Surg
2000;
69
: 1162–1166.
17. Raja SG, Berg GA. Impact of off-pump coronary artery bypass surgery
on systemic inflammation: Current best available evidence.
J Card Surg
2007;
22
: 445–455.
18. Rahmanian PB, Adams DH, Castello JG, Vassalotti J, Filsoufi F.
Early and late outcome of cardiac surgery in dialysis-dependent
patients: Single-center experience with 245 consecutive patients.
J
Thorac Cardiovasc Surg
2008;
135
: 915–919.
19. Tabata M, Takanashi S, Fukui T,
et al
. Off-pump coronary artery bypass
grafting in patients with renal dysfunction.
Ann Thorac Surg
2004;
78
:
2044–2049.
20. Bucerius J, Gummert JF, Walther T, Schmitt DV, Doll N, Falk V.
On-pump versus off-pump coronary artery bypass grafting: Impact on
postoperative renal failure requiring renal replacement therapy.
Ann
Thorac Surg
2004;
77
: 1250–1256.
21. Erentug V, Akinci E, Kirali K,
et al
. Complete off-pump coronary revas-
cularization in patients with dialysis dependent renal disease.
Tex Heart
Inst J
2004;
31
: 153–156.
22. Puskas JD, Williams WH, Duke PG,
et al.
Off-pump coronary artery
bypass grafting provides complete revascularization with reduced
myocardial injury, transfusion requirements and length of stay: A
prospective randomized comparison of two hundred unselected patients
undergoing off-pump versus conventional coronary artery bypass graft-
ing.
J Thorac Cardiovasc Surg
2003;
125
: 797–808.
23. Arom KV, Flavin TF, Emery RW,
et al
. Safety and efficacy of off-pump
coronary artery bypass grafting.
Ann Thorac Surg
2000;
69
: 704–710.
24. Shroff GR, Li S, Herzog CA. Survival of patients on dialysis having
off- pump versus on-pump coronary artery bypass surgery in the United
States.
J Thorac Cardiovasc Surg
2010;
139
: 1333–1338.
25. Manabe S, Arai H, Tanaka H, Tabuchi N, Sunamori M. Physiological
comparison of off-pump and on-pump coronary artery bypass grafting
in patients on chronic hemodialysis.
Jpn J Thorac Cardiovasc Surg
2006;
54
: 3–10.
Statins with Mediterranean diet reduces cardiovascular mortality risk
For those who have already had a heart attack or a stroke, the
combination of statins and a Mediterranean diet appears to
be the most effective choice to reduce the risk of mortality,
especially from cardiovascular causes. It is the result of an
Italian study conducted at the IRCCS Neuromed, Pozzilli,
Italy on over 1 000 adults recruited in the Moli-sani study.
The traditional Mediterranean diet is rich in fruit,
vegetables, legumes, cereals, olive oil, wine in moderation,
fish and low in meat and dairy products.
‘We found,’ Marialaura Bonaccio, epidemiologist at the
Department of Epidemiology and Prevention and first
author of the study says, ‘that statins and a Mediterranean
diet together were more effective, compared to one or
the other considered separately, in reducing the risk of
cardiovascular mortality. Likely, a Mediterranean diet
facilitated the beneficial effect of statins, which in our real-
life study were generally used at low doses.’
Researchers also analysed the potential underlying
mechanisms of this positive interaction, so far poorly
explored, between drugs and eating habits.
‘The favourable combination of statins and a
Mediterranean diet,’ explains Licia Iacoviello, head of the
Laboratory of Molecular and Nutritional Epidemiology
of the same department and professor of hygiene at the
University of Insubria, ‘appeared to act, rather than on
cholesterol levels, by reducing sub-clinical inflammation,
a condition that predisposes to a higher risk of illness and
mortality. This finding is of particular interest, especially in
the light of our observation that a high level of sub-clinical
inflammation doubled the risk of mortality in patients who
already had had a heart attack or stroke.’
‘Our data,’ says Giovanni de Gaetano, director of the
Department of Epidemiology and Prevention, ‘suggest that
we should focus more on the possible interactions between
food and drugs, an aspect largely neglected in epidemiological
research. Of course, controlled clinical trials will be needed
to clarify these findings. If our data are confirmed, new
therapeutic possibilities could be designed for those who
have already had a cardiovascular event, allowing a better
modulation of the pharmacological intervention in relation
to life habits. This is a new aspect of personalised medicine.’
Source:
Medical Brief 2019